[PDF] Top 20 Emerging utility of once-weekly exenatide in patients with type 2 diabetes

... as weekly exenatide is as an adjunct therapy to other antihyperglycemic treatment along with diet and ...exercise. Exenatide weekly is an attractive option in many patients, as the ... See full document

... and patients reduced the dosage if hypoglycemia occurred, leading to a mean titrated dose of detemir at end point ...of type 2 diabetes ...of patients achieving target A1C than with ... See full document

... versus once- daily liraglutide in the HARMONY 7 ...with once-weekly exenatide ER in the DURATION-6 trial, where liraglutide was seen to be superior to exenatide ER in terms of HbA1c ... See full document

... Abstract: Exenatide (also known as exendin-4) is a glucagon-like peptide-1 mimetic, which is indicated for the treatment of type 2 diabetes ...twice-daily exenatide (exenatide ... See full document

... compared exenatide twice daily against once weekly exenatide, one com- pared once weekly exenatide against insulin glargine, one com- pared exenatide once ... See full document

... of exenatide, and the utility of exenatide and sita‑ gliptin for improved postprandial glycemic control with an associated low risk of ...of patients may benefit from early, or even ... See full document

... insulin-treated patients and decreased by ∼ ...ExQW-treated patients. Patients treated with both insulin strategies and PIO experienced modest initial increases in weight while ExQW-treated ... See full document

... Background: Type 2 diabetes mellitus (T2DM) is a complex disorder in which interactions between environmental and genetic factors result in the development of insulin resistance (in most cases) and ... See full document

... a once-weekly glucagon-like peptide-1 receptor agonist, which has been on the market in the USA since ...outperformed exenatide when added to a regimen of metformin with pioglitazone as well as ... See full document

... Abstract: Exenatide is a GLP-1 receptor agonist approved for use in type 2 diabetes ...for exenatide with primary glycemic effects of the twice daily formulation on prandial glucose ... See full document

... receiving exenatide QW from weeks 0 to 30 and weeks 30 to 104 (ITT population) are described in Table ...for exenatide BID treatment from weeks 0 to 30 was previously reported ...with exenatide were ... See full document

... liraglutide once daily, and exenatide QW. Recent American Diabetes Association treatment guidelines recommend a GLP-1 receptor agonist as one option for second-line therapy in patients not ... See full document

... in patients with uncontrolled type 2 diabetes mellitus (baseline HbA 1C ...of type 2 diabetes mellitus ...1). Exenatide was included as an open-label clinical ...in ... See full document

... Abstract: Exenatide once weekly (EQW), the first glucose-lowering agent for type 2 diabetes that is dosed one time per week, contains exenatide encapsulated in ... See full document

... 4,328 patients with type 2 diabetes were pooled from eight clinical studies of exenatide QW (Figure 1), including 1,934 patients treated with exenatide QW, 606 ... See full document

... the exenatide once-weekly ...on diabetes duration, diabetes-related complications, glycated hemoglobin levels, and other clinical characteristics were not available in the ...that ... See full document

... in patients categorized by their concomitant glucose ...in patients with T2DM who were treated with exenatide ER for 24–30 ...weeks. Patients were classified into subgroups according to their ... See full document

... in patients being treated with EXE 10 µ g SC ...EXE, patients that experience severe abdominal pain with or without nausea/vomiting, should seek immediate medical attention to rule out ... See full document

... million patients in 49 states, and includes demographic data, vital signs, laboratory orders and results, medication list entries and prescriptions, and diagnoses or ...in patients with ... See full document

... tolerability, exenatide QW is quite expensive, which may limit its application in less developed ...that exenatide QW has therapeutic effects in common with most hypoglycemic drugs, and even better than ... See full document